The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.
Discussing Epstein-Barr Virus and Multiple Sclerosis: Bruce Bebo, PhDMarch 1st 2022
The executive vice president of the National MS Society spoke on recently published data suggesting the relationship between EBV and MS, also sharing his opinion on the potential of vaccines. [WATCH TIME: 2 minutes]
Using Radiologic Markers to Predict Chronic Active Lesion Evolution in MS: Matthew Schindler, MD, PhDMarch 1st 2022
The assistant professor of neurology at the University of Pennsylvania discussed his abstract at ACTRIMS Forum using 7T MRI features of newly developed MS lesions to predict chronic active lesions. [WATCH TIME: 4 minutes]
ACTRIMS Forum Takeaways and Unmet Needs in Multiple Sclerosis: Bruce Bebo, PhDFebruary 27th 2022
The executive vice president of the National MS Society spoke on the primary theme of ‘biomarkers’ at this year’s meeting, as well as the areas he believes require the most attention for patients with MS. [WATCH TIME: 3 minutes]
Cortical Lesion Burden Associated With Disability Worsening, Transition to Progressive Multiple SclerosisFebruary 27th 2022
Three-year follow-up data presented at the ACTRIMS Forum 2022 suggest cortical lesion burden, particularly subpial lesions, is the primary driver of worsening disability and conversion to secondary progressive MS.
CNM-Au8 Shows Effects on Brain Bioenergetic Metabolism, Supports Candidacy in Multiple SclerosisFebruary 27th 2022
Mechanistic data from the phase 2 REPAIR-MS trial support blinded efficacy data from the VISIONARY-MS trial, suggesting that Clene Nanomedicine’s investigational CNM-Au8 has the potential to drive clinically meaningful improvements in recognized MS functional end points.
Cladribine Shows Long-Term Efficacy in Delaying MS Conversion, Favorable Efficacy Compared With Other Oral DMTsFebruary 26th 2022
A pair of datasets from the CLASSIC-MS and GLIMPSE studies of cladribine (Mavenclad; EMD Serono) suggest that the oral tablet sustained delayed conversion to clinically definite MS as well as favorable efficacy to dimethyl fumarate, fingolimod, and teriflunomide.
Paramagnetic Rim Lesions Demonstrate Diagnostic Potential for MS ReferralsFebruary 26th 2022
Using a diagnostic threshold of at least 1 paramagnetic rim lesion, MS was identified with a sensitivity of 80% and specificity of 88%, which increased to 95% after excluding patients with RIS and CIS.
Swank and Wahls Diets Show Positive Impact on Weight, Cholesterol in Relapsing MSFebruary 25th 2022
At the 12- and 24-week time points, patients in both diet groups demonstrated statistically significant differences in total cholesterol, low-density lipoprotein, body weight, and body mass index.
Discussing Economic Burden for Patients With Multiple Sclerosis: Bruce Bebo, PhDFebruary 24th 2022
The executive vice president of the National MS Society spoke on the updated data from an analysis on economic burden, which illustrated the ‘staggering’ impact of the disease. [WATCH TIME: 4 minutes]
Calorie Restriction Diets Associated With Reduction in Memory T Cell Subsets in Multiple SclerosisFebruary 24th 2022
Investigators conducted a study to assess the effects of CR diet on immune cell subsets, concluding that observed changes could be mediated by changes in classes of lipid metabolites.
Low Neutralizing Antibody Incidence, High Antidrug Antibody Rates Observed in MS With Ublituximab TreatmentFebruary 24th 2022
There were no statistically significant differences in infusion-related reactions among patients with multiple sclerosis who tested positive or negative for treatment-emergent antidrug antibodies.
Gearing Up For the 2022 ACTRIMS Forum: Jeffrey Cohen, MDFebruary 24th 2022
The professor of neurology at Cleveland Clinic and president of ACTRIMS noted his excitement for this year’s Forum, which will feature presentations on a variety of topics in the field of multiple sclerosis. [WATCH TIME: 2 minutes]
Understanding Mechanisms of MS Chronic Inflammation: Jemima Akinsanya, DO, and Daniel Reich, MD, PhDApril 9th 2021
The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.